Patients undergoing cancer treatment are at a heightened risk for acute kidney injury (AKI), but a large retrospective analysis found no increased risk related to exposure to glucagon-like peptide-1 (GLP-1) receptor agonist drugs. The study, presented at the American Society of Nephrology Kidney Week 2024 Annual Meeting, included 14,783 cancer patients treated with anticancer therapies at Ochsner Medical Center. While hormonal therapy was found to have a lower risk for AKI, GLP-1 use was not significantly associated with AKI risk. Previous reports of GLP-1-related AKI, including two cases with semaglutide treatment, were mentioned, but the new findings show no significant association during cancer treatment.
Source link
GLP-1s Show No Link to AKI With Anticancer Therapy
